Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that combination therapy with metformin plus rosiglitazone provided superior durability of glycemic control compared with metformin alone, with significantly lower treatment failure rates (38.6 vs. 51.7%), and metformin plus lifestyle was intermediate. Herein we describe the temporal changes in measures of β-cell function and insulin sensitivity over a 4-year period among the three treatments. RESEARCH DESIGN AND METHODS: TODAY participants (699) were tested periodically with an oral glucose tolerance test to determine insulin sensitivity (1/fasting insulin [1/IF]), insulinogenic index (△I30/△G30) or C-peptide index (△C30/△G30), and β-cell function relative to insulin sensitivity (oral disposition index [oDI]). RESULTS: During the first 6 months, metformin plus rosiglitazone exhibited a significantly greater improvement in insulin sensitivity and oDI versus metformin alone and versus metformin plus lifestyle; these improvements were sustained over 48 months of TODAY. Irrespective of treatment, those who failed to maintain glycemic control had significantly lower β-cell function (∼50%), higher fasting glucose concentration, and higher HbA1c at randomization compared with those who did not fail. CONCLUSIONS: The beneficial change in insulin sensitivity and the resultant lower burden on β-cell function achieved in the first 6 months with metformin plus rosiglitazone appear to be responsible for its superior glycemic durability over metformin alone and metformin plus lifestyle. However, initial β-cell reserve and HbA1c at randomization are independent predictors of glycemic durability. Therefore, efforts to preserve β-cell function before significant loss occurs and to reduce HbA1c may be beneficial in the treatment of youth with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Baseline adjusted geometric mean ± SE asymmetric limits (obtained as exp[mean ± SE of log values]) of OGTT-derived measures of insulin sensitivity (1/IF) (A), insulinogenic index (△I30/△G30) (B), and oDI ([1/IF] × [△C30/△G30]) (C) in the three treatment groups over 48 months of follow-up in TODAY, analyzed using log-transformed values. The P value refers to the overall effect of treatment group assignment in the longitudinal models for the various parameters under question within the groups.](https://figures.cochat.ai/paper-figures/be1b067684cd4881bcf619e3acd41518/effects-of-metformin-metformin-plus-rosiglitazone-and-metformin-plus-lifestyle-figure-1.jpg)
![Figure 2 Baseline adjusted geometric mean ± SE asymmetric limits (obtained as exp[mean ± SE of log values]) of OGTT-derived measures by treatment failure with the three treatment groups combined, analyzed using log-transformed values. A: Insulin sensitivity (1/IF). B: Insulinogenic index (△I30/△G30). C: oDI ([1/IF] × [△C30/△G30]). The P value refers to the overall effect of failed vs. not failed group assignment in the longitudinal models for the various parameters under question within the two groups.](https://figures.cochat.ai/paper-figures/20b5098a6cb74952b4dc2dac4d181449/effects-of-metformin-metformin-plus-rosiglitazone-and-metformin-plus-lifestyle-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Affected young people have a more rapid deterioration in blood glucose levels, an attenuated response to diabetes medication, and more rapid development of diabetes complications (269 -273).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [272]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A 20-35 % decline in beta cell function annually in 10-19 year olds has been reported compared to the ~7% loss in older individuals with T2DM 23 .”
From Type 2 diabetes in adolescents and young adults (2018) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Once treated with metformin after progressing to T2D, youth show a greater rate of treatment failure than adults ( 52 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes
TODAY Study Group (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109333 · Cited by 971
Self-citationThe Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes
Kahn, S. E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7713 · Cited by 660
Copeland, K. C., Zeitler, P., Geffner, M., Guandalini, C., Higgins, J., Hirst, K., Kaufman, F. R., Linder, B., Marcovina, S., McGuigan, P., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1642 · Cited by 464
Effect of Metformin in Pediatric Patients With Type 2 Diabetes
Jones, K. L., Arslanian, S., Peterokova, V. A., Park, J.-S., & Tomlinson, M. J. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.89 · Cited by 392 · cited 1×
“Even though metformin was effective in the short-term over 16 weeks (2), it remained unknown whether this effect was durable until the results of the TODAY (Treatment Options for type 2 Diabetes in Adolescents andYouth) trial showed.”
BackgroundThe TODAY Study Group (2007) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00237.x · Cited by 260
Self-citationKahn, S. E., Lachin, J. M., Zinman, B., Haffner, S. M., Aftring, R. P., Paul, G., Kravitz, B. G., Herman, W. H., Viberti, G., Holman, R. R., et al. (2011) · Diabetes · doi:10.2337/db10-1392 · Cited by 249 · cited 5×
“The ADOPT (A Diabetes Outcome Progression Trial) study of drugnaive adults with type 2 diabetes showed that the insulinogenic index declined at a rate of ;7–11% per year (12).”
BackgroundMethodResultInfluentialHyperinsulinemia in African-American Children
Arslanian, S. A., Saad, R., Lewy, V., Danadian, K., & Janosky, J. (2002) · Diabetes · doi:10.2337/diabetes.51.10.3014 · Cited by 236 · cited 1×
“In addition, differences in insulin clearance in different racial groups (21,22) could confound the insulinogenic index data.”
BackgroundThe Rosiglitazone Story — Lessons from an FDA Advisory Committee Meeting
Rosen, C. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078167 · Cited by 207 · cited 1×
“However, TODAY was designed and initiated prior to the discovery of the adverse effects of rosiglitazone (26).”
BackgroundGungor, N., Bacha, F., Saad, R., Janosky, J., & Arslanian, S. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.638 · Cited by 186
Cited by
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
KANALEY, J. A., COLBERG, S. R., CORCORAN, M. H., MALIN, S. K., RODRIGUEZ, N. R., CRESPO, C. J., KIRWAN, J. P., & ZIERATH, J. R. (2022) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002800 · Cited by 931
“In a multicenter study in youth with T2D (the TODAY Study), metformin therapy managed glycemia in half of participants, and the addition of rosiglitazone, but not lifestyle changes including PA, was superior to metformin alone (126,127).”
Metadata
- Authors
- TODAY Study Group
- Corresponding author
- TODAY Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-05-15
- Volume
- 36
- Issue
- 6
- Pages
- 1749-1757
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3661836
- OpenAlex
- W59232989
- Cited by
- 288
- References
- 25
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 30 · 2023: 25 · 2022: 37 · 2021: 28 · 2020: 27 · 2019: 16 · 2018: 23 · 2017: 12 · 2016: 12 · 2015: 16 · 2014: 18 · 2013: 8
- FWCI
- 14.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000130, UL1TR000005, UL1TR000448, UL1TR000439)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061239, U01DK061212, U01DK061254, U01DK061242, U01DK061230)
- National Center for Research Resources (M01RR000125, UL1RR024989, UL1RR025758, M01RR001066, UL1RR024153, UL1RR024134, M01RR000043, M01‐RR00043‐45, M01RR014467, M01RR000069, UL1RR024992, UL1RR024139, M01RR000084, M01RR000036, UL1RR025780)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- metformin, rosiglitazone, insulin sensitivity, beta-cell function, oral disposition index, insulinogenic index, treatment failure, beta-cell reserve
- MeSH terms
- Adolescent, Child, Diabetes Mellitus, Type 2, Drug Combinations, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Life Style, Male, Metformin, Thiazoles, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY. https://app.cochat.ai/papers/10.2337/dc12-2393
- The paper
- TODAY Study Group. (2013). Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY. Diabetes Care. https://doi.org/10.2337/dc12-2393
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.